536 related articles for article (PubMed ID: 25387808)
21. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
Zielinski C; Lang I; Beslija S; Kahan Z; Inbar MJ; Stemmer SM; Anghel R; Vrbanec D; Messinger D; Brodowicz T
Br J Cancer; 2016 Jan; 114(2):163-70. PubMed ID: 26657657
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D
Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120
[TBL] [Abstract][Full Text] [Related]
23. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
[TBL] [Abstract][Full Text] [Related]
26. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.
Miles DW; Diéras V; Cortés J; Duenne AA; Yi J; O'Shaughnessy J
Ann Oncol; 2013 Nov; 24(11):2773-80. PubMed ID: 23894038
[TBL] [Abstract][Full Text] [Related]
27. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
Vrdoljak E; Marschner N; Zielinski C; Gligorov J; Cortes J; Puglisi F; Aapro M; Fallowfield L; Fontana A; Inbar M; Kahan Z; Welt A; Lévy C; Brain E; Pivot X; Putzu C; González Martín A; de Ducla S; Easton V; von Minckwitz G
Ann Oncol; 2016 Nov; 27(11):2046-2052. PubMed ID: 27502725
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J
Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R
J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087
[TBL] [Abstract][Full Text] [Related]
30. First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.
Masuda N; Takahashi M; Nakagami K; Okumura Y; Nakayama T; Sato N; Kanatani K; Tajima K; Kashiwaba M
Jpn J Clin Oncol; 2017 May; 47(5):385-392. PubMed ID: 28158579
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib in locally advanced or metastatic breast cancer.
Gradishar WJ
Expert Opin Investig Drugs; 2012 Aug; 21(8):1177-91. PubMed ID: 22616580
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
[TBL] [Abstract][Full Text] [Related]
33. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Qi WX; Tang LN; He AN; Shen Z; Yao Y
Breast; 2013 Jun; 22(3):314-9. PubMed ID: 22901442
[TBL] [Abstract][Full Text] [Related]
34. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
35. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
38. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V
J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
